GlyProVac ApS
CVR 39724758 · Private limited company (ApS) · Active · Low risk
GlyProVac ApS is a Private limited company (ApS), founded on , based in Odense SØ. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 1.1% over the next 12 months, which is 0.8 times the average for Danish companies. 7 annual reports have been published. The latest annual report (30 Jun 2025) shows equity of DKK -832k and a net result of DKK -5.2m. CEO: Ann Zahle Andersen.
Bankruptcy risk for GlyProVac ApS
0.8 × the average (1.41%) · higher risk than 74% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 39724758
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (8 years)
- Address
- Rørhatten 4
5220 Odense SØ - Municipality
- Odense
- Industry
- Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater - Share capital
- DKK 155k
- Employees
- 3 (2018)
- Auditor
- PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 7 |
| Missing annual report | No |
| Negative equity | Yes |
| Equity ratio | -17.9% |
| Current ratio | 864% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 3 |
| Going-concern uncertainty | Yes |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -2.1m | DKK -577k |
| Net profit | DKK -5.2m | DKK -3.0m |
| Equity | DKK -832k | DKK -654k |
| Total assets | DKK 4.6m | DKK 4.4m |
| Cash | DKK 2.4m | – |
| Short-term debt | DKK 534k | – |
| Avg. employees | 6 | – |
Latest annual report: Reporting class B · auditor's statement: Erklæring om udvidet gennemgang · PricewaterhouseCoopersStatsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jul 2024 – 30 Jun 2025 | 182 | ||
| 1 Jul 2023 – 30 Jun 2024 | 172 | ||
| 1 Jul 2022 – 30 Jun 2023 | 98 | ||
| 1 Jul 2021 – 30 Jun 2022 | 131 | ||
| 1 Jul 2020 – 30 Jun 2021 | 153 | ||
| 1 Jul 2019 – 30 Jun 2020 | 126 | ||
| 3 Jul 2018 – 30 Jun 2019 | 131 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Ann Zahle Andersen | Current | |
| Board | Willem Adriaan de Jongh | Current | |
| Board | Allan Rosetzsky | Current | |
| Board | Kirsten Winther | Current | |
| Board | Ann Zahle Andersen | Current | |
| Board | Peter Smedegaard | ||
| Board | Anders Boysen | ||
| Board | Ann Zahle Andersen | ||
| Board | Kirsten Winther | ||
| Board | Tommi Petteri Kainu | ||
| Board | Tommi Petteri Kainu | ||
| Owner (5%) | I/S Rødeledsvej | Current | |
| Owner (33%) | GlycoPharma Holding ApS | Current | |
| Owner (10%) | Rossi Finans ApS | Current | |
| Owner (10%) | Bente Kristiansen | Current | |
| Owner (20%) | Uddannelses- og Forskningsstyrelsen | ||
| Owner (67%) | GlycoPharma Holding ApS | ||
| Owner (5%) | SYDDANSK INNOVATION ApS | ||
| Owner (25%) | Uddannelses- og Forskningsstyrelsen | ||
| Owner (50%) | GlycoPharma Holding ApS | ||
| Owner (5%) | Marigold Innovation ApS | ||
| Owner (5%) | Niels Hermann Kristiansen | ||
| Owner (20%) | Uddannelses- og Forskningsstyrelsen | ||
| Owner (5%) | AR CONSULT ApS | ||
| Owner (10%) | Niels Hermann Kristiansen | ||
| Owner (10%) | Uddannelses- og Forskningsstyrelsen | ||
| Auditor | PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB | Current | |
| Founder | GlycoPharma Holding ApS | Current |
The CEOs' other companies
Ann Zahle Andersen – 1 other companies
- Zahle Holding ApS Active
Address history (0 moves)
| Rørhatten 4, 5220 Odense SØ |
Employees per year
Other companies at the same address
- Bioglyco ApS Active
- Boysen Bio ApS Active
- GlycoPharma Holding ApS Active
Similar companies in Odense
- RhomeoX ApS Odense M
- Lucia Care ApS Odense C
- CorporateHealth International ApS Odense M
- AsoGen Therapeutics IVS Odense S
- CanFarm ApS Odense SV
- CorporateHealth Denmark ApS Odense M
- PROFYLAKSE ApS Odense NV
- VIMINCO A/S Odense S
Questions and answers about GlyProVac ApS
Has GlyProVac ApS gone bankrupt?
No, GlyProVac ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of GlyProVac ApS?
Our model estimates a bankruptcy risk of 1.1% over the next 12 months (low risk), which is 0.8 times the average for Danish companies.
Who is the CEO of GlyProVac ApS?
Ann Zahle Andersen is the CEO of GlyProVac ApS.
Who is the auditor of GlyProVac ApS?
GlyProVac ApS most recently used PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB.
When was GlyProVac ApS founded?
GlyProVac ApS was founded on 3 July 2018.
What is the equity of GlyProVac ApS?
Equity was DKK -832k according to the annual report for the period ending 30 June 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.